



Press Release

TxCell to present at ROTH Capital Partners investor conference in US

TxCell invited to speak at largest US meeting for investors in emerging growth companies

Valbonne, France, February 26, 2015 – TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that Damian Marron, CEO, TxCell, will present to selected leading institutional investors at the 27th Annual ROTH Conference 2015. The conference will take place on March 8 – 11, 2015 in Dana Point, CA, USA.

TxCell's corporate presentation is scheduled for Wednesday, March 11, 2015 at 10:30 a.m. PST at The Ritz Carlton, Track 4, The Colonnade, 1 Ritz Carlton Dr, Dana Point, CA.

In the presentation, Damian Marron will provide an overview of TxCell and its personalized T cell immunotherapy platform ASTrIA. Additional details will also be provided to institutional investors in one on one meetings at the conference. Topics covered include development of Ovasave[®], TxCell's lead product candidate in refractory Crohn's disease, for which a multinational placebo-controlled phase IIb clinical study is ongoing, Col-Treg, TxCell's second product candidate developed in autoimmune uveitis, a rare eye disease for which a phase I/II proof of principle clinical trial is planned to start in the first half of 2015, and TxCell's innovative, cost-effective business model. Details of the next milestones for TxCell, including those of the EUR 76 million partnership with Ferring / Trizell will also be provided.

The Roth Capital Partners conference enables CEOs from small-cap growth companies to make presentations to leading institutional investors. This annual event is the largest in the US for emerging growth companies. It provides a concentrated forum where institutional investors can meet the executives of growth companies. Investors and companies are personally selected by Roth Capital's research team.

“TxCell has continued to develop rapidly since its IPO last year. We are now in a very strong position, with one of the most advanced, innovative personalized T-cell immunotherapy multi-product pipelines. This is also backed up by an extensive patent portfolio, a partnership with a major pharmaceutical company with a recent extension, a GMP validated manufacturing process and a robust discovery platform,” said Damian Marron, CEO TxCell. “In addition, we have achieved additional important milestones. Hence it is very important to inform and update investors and members of the US financial community who are active in the small-cap markets at the respected ROTH Conference. This will give them an additional unique insight into investment hypotheses for TxCell’s advanced therapies-based treatments.”

About Roth Capital Partners, LLC

With corporate headquarters in Newport Beach, California and offices in strategic locations in the Western United States, Roth Capital Partners, LLC is a full service investment bank serving corporate, and institutional clients throughout the world Offering a wide array of investment banking services including: initial public offerings, follow-ons, PIPEs, private placements, mergers and acquisitions, investment research, and institutional sales and trading, the firm is perhaps best known for finding, funding and fostering the growth of emerging companies. Visit the Roth Capital Partners website at www.rothcp.com.

About TxCell

TxCell develops innovative, cost-effective, personalized T cell immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need. TxCell has created ASTrIA, a unique and proprietary technology platform based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs). The company has initiated a phase IIb study of its lead product candidate, Ovasave® in refractory Crohn’s disease patients. This follows a phase I/IIa study in the same patient population reporting positive clinical efficacy and good tolerability. TxCell has a strategic partnership for the development of Ovasave with the Swiss company Trizell Holding SA and Ferring International Center remains the intended final commercializing party. Both companies are affiliates of the Dr Frederik Paulsen Foundation. TxCell’s second product candidate, Col-Treg is for the treatment of autoimmune uveitis, a rare disease of the eye. A placebo-controlled, dose-ranging proof of principle clinical study is planned to start in the first half of 2015. Listed on Euronext-Paris, TxCell, a spin-off of Inserm (France’s National Institute for Health and Medical Research) is located in the Sophia Antipolis technology park, Nice, France. The company has 63 employees based at its headquarters and at its manufacturing site in Besançon. For more information, please visit www.txcell.com

Practical Information about TxCell shares:**ISIN code** FR0010127662**Ticker code** TXCL**Disclaimer:**

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated.

CONTACTS

TxCell	Image Box – Press relations	NewCap – Investor relations
BD & Communication Department Tel: +33(0) 497 218 300 Fax: +33(0) 493 641 580 contact@txcell.com	Neil Hunter / Michelle Boxall Tel: +44(0) 20 8943 4685 neil.hunter@imageboxpr.co.uk michelle.boxall@imageboxpr.co.uk	Julien Perez / Pierre Laurent Tel: +33 (0)1 44 71 98 52 txcell@newcap.fr